Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Common Equity (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Common Equity for 7 consecutive years, with $26.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 7.07% to $26.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.2 million through Dec 2025, up 7.07% year-over-year, with the annual reading at $26.2 million for FY2025, 7.07% up from the prior year.
  • Common Equity hit $26.2 million in Q4 2025 for Eton Pharmaceuticals, up from $23.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $26.2 million in Q4 2025 to a low of $11.2 million in Q3 2022.
  • Historically, Common Equity has averaged $17.7 million across 5 years, with a median of $16.4 million in 2023.
  • Biggest five-year swings in Common Equity: soared 1028.24% in 2021 and later tumbled 37.91% in 2022.
  • Year by year, Common Equity stood at $17.6 million in 2021, then fell by 25.82% to $13.1 million in 2022, then increased by 18.34% to $15.5 million in 2023, then surged by 57.83% to $24.4 million in 2024, then increased by 7.07% to $26.2 million in 2025.
  • Business Quant data shows Common Equity for ETON at $26.2 million in Q4 2025, $23.1 million in Q3 2025, and $24.0 million in Q2 2025.